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The recent approval of sapropterin dihydrochloride, the synthetic form of 6[R]-L-erythro-5,6,7,8-tetrahydro-
biopterin (BH4), for the treatment of phenylketonuria (PKU) as the first pharmacological chaperone drug
initiated a paradigm change in the treatment of monogenetic diseases. Symptomatic treatment is now
replaced by a causal pharmacological therapy correcting misfolding of the defective phenylalanine hydroxyl-
ase (PAH) in numerous patients. Here, we disclose BH4 responsiveness in Pah
enu1, a mouse model for PAH
deficiency. Loss of function resulted from loss of PAH, a consequence of misfolding, aggregation, and accel-
erated degradation of the enzyme. BH4 attenuated this triad by conformational stabilization augmenting the
effective PAH concentration. This led to the rescue of the biochemical phenotype and enzyme function
in vivo. Combined in vitro and in vivo analyses revealed a selective pharmaceutical action of BH4 confined
to the pathological metabolic state. Our data provide new molecular-level insights into the mechanisms
underlying protein misfolding with loss of function and support a general model of pharmacological
chaperone-induced stabilization of protein conformation to correct this intracellular phenotype. Pahenu1
will be essential for pharmaceutical drug optimization and to design individually tailored therapies.
INTRODUCTION
The biological and medical significance of protein misfolding
as a basis of disease is increasingly recognized. Distinct patho-
physiological mechanisms underlying protein misfolding dis-
orders are known. In neurodegenerative diseases such as
Alzheimer’s or Parkinson’s disease, misfolded proteins
accumulate and form insoluble aggregates associated with
molecular and clinical dysfunction (1–3). In other disorders,
missense mutations cause unfavorable structural rearrange-
ments resulting in conformational destabilization, rapid degra-
dation and a lack of the functional protein (4–8). The latter
group of protein misfolding diseases with loss of function
now comes into focus of research. More than 20 monogenetic
[e.g. cystic fibrosis, phenylketonuria (PKU)] and acquired
(e.g. p53 mutations) disorders are known to be associated
with this molecular phenotype (Supplementary Material,
Table S1).
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Pharmacological chaperones are small-molecule chemical
compounds that manipulate dysfunctional biological systems
by stabilizing protein conformation in misfolding diseases
(7–11). The first pharmacological chaperone drug, BH4
(Kuvanw), was approved in 2008 for the treatment of PKU
(MIM 261600), the most frequent genetic disorder of amino
acid catabolism. Pharmacological doses of BH4, the natural
cofactor of the deficient enzyme phenylalanine hydroxylase
(PAH), restore enzyme function by a mechanism other than
its cofactor action in a significant share of patients (12).
First in vitro studies using purified PAH pointed to stabiliz-
ation of the misfolded protein against denaturation and degra-
dation (13–16). In wild-type (17,18) and transgenic mice with
deficiency in BH4 biosynthesis (19), supplementation of BH4
enhanced the amount of hepatic wild-type PAH protein and
in vivo enzyme activity. However, an animal model showing
the particular phenotype of BH4-responsive PAH deficiency
was not available for approval. This precluded the elucidation
of the molecular mechanisms causing loss of function and the
mode of action underlying pharmacological chaperone therapy
in vivo. The aim of this study, therefore, was to identify a
mouse model for BH4-responsive PAH deficiency that would
enable in vitro and in vivo experimental insight into the bio-
logical processes associated with PAH deficiency and into
the mechanisms of therapeutic correction of the loss-of-
function phenotype at the molecular level.
Two mouse strains produced by germline mutagenesis har-
boring defective Pah genes are available (20). The V106A
mutation in Pahenu1 leads to a mild hyperphenylalaninemia
phenotype (21), whereas Pahenu2 (F263S) shows severe PKU
(www.pahdb.mcgill.ca) (20,22,23). Although Pahenu1 was
thoroughly studied (20–24), it was not recognized to be a
model for the new clinical entity of BH4-responsive PKU.
The present study disclosed misfolding-induced PAH
deficiency and its pharmacological rescue by BH4 in
Pahenu1, reflecting the situation in human hyperphenylalanine-
mia. Besides accelerated degradation, we observed aggregate
formation of the PAH protein in vitro and in vivo, revealing
a novel pathophysiological aspect of protein misfolding in
the particular group of conformational disorders with loss of
function. Moreover, we showed that BH4 corrects the bio-
chemical phenotype by stabilizing the target protein confor-
mation, and we retraced the mode of action of the
pharmacological chaperone on misfolding, aggregation and
degradation of the PAH protein in vivo. The animal model pre-
sented provided insights into general mechanisms underlying
protein misfolding with loss of function and helped to under-
stand the pharmacological chaperone effect of BH4 at a mol-
ecular level. This knowledge will allow us to exploit the
resources of chemical compound libraries to design future
therapeutic agents for other protein misfolding diseases.
RESULTS
Murine PAH is a suitable model for the human
phenylalanine hydroxylating system
It was previously hypothesized that the total activity of murine
PAH is higher than that of human PAH due to differences in
PAH regulation by substrate and cofactor (22,25). We
re-evaluated whether Mus musculus is a suitable model for
issues related to human PAH by generating the first complete
kinetic data from recombinant murine PAH proteins.
The specific activity of tetrameric murine wild-type PAH
expressed in E. coli as fusion protein with maltose binding
protein (MBP) was well comparable to that of human wild-
type PAH. Apparent affinities of the enzymes for the substrate
L-phenylalanine and the BH4 cofactor, cooperativity for sub-
strate binding and substrate-induced enzyme activation did
not differ significantly between murine and human PAH
(Table 1). However, total PAH enzyme activity and the
PAH protein amount in crude liver lysates of wild-type mice
were about twice as high as in human liver (Fig. 1A). Thus,
murine and human PAH show similar specific activity and
analogous regulation, whereas the inconsistency between
specific and total PAH enzyme activity is due to differences
in the PAH protein amount in vivo.
Loss of function in Pahenu1 is associated with reduced
amounts of PAH protein
Next, we related specific enzyme activity in vitro to residual
protein amount and enzyme function in vivo.
13C-phenylalanine breath tests assessing phenylalanine oxi-
dation are a good measure for overall in vivo PAH activity
in humans as well as in mice (12,17,26). The cumulative
recovery of 13CO2 representing
13C-phenylalanine turnover
was 33% for Pahenu1 and 12% for Pahenu2 when compared
with wild-type mice. The mild reduction in enzyme activity
in Pahenu1 still induced an increase in mean blood phenyl-
alanine concentration to 189 mmol/l (wild-type 76 mmol/l),
reflecting a mild hyperphenylalaninemia phenotype, whereas
Pahenu2 showed phenylalanine concentrations in the range of
classical PKU (1144 mmol/l) (Fig. 1B). Data for PAH activity
and blood phenylalanine levels are in agreement with previous
studies using crude liver lysates (17,22).
Table 1. Steady-state enzyme kinetic parameters of human and murine PAH
proteins
Species Specific activitya
(nmol Tyr/
min × mg
protein)
[S]0.5
b
(mM)
Km
c
(mM)
hb Activation
fold
WT-HsPAH 3115+149 155+6 24.0+3 3.0 3.0
WT-MmPAH 2628+293 175+34 22.0+5 2.6 3.1
Recombinant tetrameric human (WT-HsPAH) and murine (WT-MmPAH)
wild-type PAH were expressed as MBP–PAH fusion proteins in E. coli.
Apparent affinities for L-phenylalanine ([S]0.5), BH4 (Km) and the Hill
coefficient (h) as a measure of cooperativity are shown. Activation fold
represents substrate activation as the ratio of specific activity with and without
prior incubation with L-phenylalanine. Values are given as means+SEM of
n ¼ 3 experiments.
aSpecific activity was determined at standard L-phenylalanine (1 mM) and BH4
(75 mM) concentrations with L-phenylalanine pre-incubation.
bApparent affinities for L-phenylalanine ([S]0.5) and the Hill coefficient (h)
were determined at variable L-phenylalanine concentrations (0–4.5 mM) and
standard BH4 concentration (75 mM).
cApparent affinities for BH4 (Km) were determined at variable BH4
concentrations (0–700 mM) and standard L-phenylalanine concentration
(1 mM).
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Recombinant expression and purification of variant murine
PAH allowed for detailed analysis of the catalytic function
of Pahenu1 (V106A) and Pahenu2 (F263S). The latter harbors
a mutation in the catalytic core, leading to a near-complete
loss of specific PAH activity, whereas V106A undergoes
loss of function by distinct molecular mechanisms. Compel-
lingly, the V106A replacement in the regulatory domain
resulted in unimpaired specific enzyme activity. Likewise,
positive cooperativity (h, 2.6) and apparent affinity to the
cofactor (Km, 22.0 mM) were almost identical to wild-type.
But still, regulatory characteristics of PAH kinetics were
altered with respect to a moderate increase in affinity to the
substrate and a complete loss of substrate activation
(Table 2). These findings point to a structural change of the
V106A variant, which may have adopted a pre-activated
‘r-state’-like conformation. Decreased in vivo enzyme activity
(13C-phenylalanine oxidation) was confirmed by ex vivo ana-
lyses (liver lysates) and in eukaryotic expression systems
(COS-7 cells and TnT) (Fig. 1C). This was attended by a
reduced amount of PAH protein in both the physiological
context of the liver and the artificial expression system
COS-7. These results suggested misfolding-induced proneness
of V106A to degradation, potentially mediated by increased
proteolytic turnover. Indeed, the presence of protease inhibi-
tors led to an increase in the PAH protein amount in
Pahenu1, but not in wild-type liver lysates (Fig. 1D).
Thus, loss of function in Pahenu1 is associated with reduced
amounts of PAH protein and points to protein misfolding as
the pathogenic trigger.
Figure 1. Comparison of human and murine PAH and characterization of PAH deficiency in Pahenu1 and Pahenu2 mice. (A) Relative PAH activity (A) and PAH
protein amount (P) in human and murine crude liver lysates. Data were normalized to murine samples and are given as means+ s.e.m. of n ¼ 3 experiments. (B)
Phenylalanine oxidation and blood phenylalanine levels of wild-type (WT, n ¼ 6), Pahenu1 (ENU1, n ¼ 10) and Pahenu2 (ENU2, n ¼ 4) mice in vivo. The
phenylalanine oxidation rate was assessed by determination of the cumulative 13CO2 recovery at 104 min (CUM104) after i.p. application of
13C-phenylalanine
(15 mg/g body weight). Values are given as means+ s.e.m. (C) Relative PAH activity (left) and PAH protein amount (right) of murine wild-type PAH (WT) and
ENU1/V106A-PAH in crude liver lysates, expressed in COS-7 cells and in the TnT system. Data were normalized to WT-PAH and are given as means+ s.e.m of
n ¼ 3 experiments. (D) Protection of PAH protein by protease inhibitors (PI). Liver lysates of wild-type mice (WT) and Pahenu1 (ENU1) mice in the absence or
presence of PI. Data of n ¼ 1 experiment were normalized to conditions without PI.
Table 2. Steady-state enzyme kinetic parameters of wild-type and variant mur-
ine PAH proteins
Genotype Specific activitya
(% of wild-type)
[S]0.5
b
(mM)
Km
c
(mM)
hb Activation
fold
WT 100 175+34 22.0+5 2.6 3.1
V106A 108+14 103+24 22.0+6 2.6 1.0
F263S 4+17 — — — 0.8
Recombinant tetrameric wild-type (WT) and variant (V106A, F263S) murine
PAH proteins were expressed as MBP–PAH fusion proteins in E. coli.
Apparent affinities for L-phenylalanine ([S]0.5), BH4 (Km) and the Hill
coefficient (h) as a measure of cooperativity are shown. Activation fold
represents the ratio of specific activity with and without prior incubation with
L-phenylalanine. Values are given as means+ s.e.m. of n ¼ 3 experiments. The
marked reduction in the specific PAH activity of F263S precluded the
determination of further enzyme kinetic parameters.
aSpecific activity was determined at standard L-phenylalanine (1 mM) and BH4
(75 mM) concentrations with L-phenylalanine pre-incubation.
bApparent affinities for L-phenylalanine ([S]0.5) and the Hill coefficient (h)
were determined at variable L-phenylalanine concentrations (0–4.5 mM) and
standard BH4 concentration (75 mM).
cApparent affinities for BH4 (Km) were determined at variable BH4
concentrations (0–700 mM) and standard L-phenylalanine concentration (1 mM).
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Misfolding induces PAH aggregation and degradation
in vitro
The protein misfolding phenotype of Pahenu1 was analyzed by
steady state, kinetic and thermal aggregation and degradation
assays using recombinant protein. We monitored the oligo-
meric state of murine wild-type and V106A-PAH following
affinity chromatography. Size-exclusion chromatography
(SEC) revealed a similar tetramer-to-dimer ratio of both pro-
teins, and this corresponded to human (4,27) and rat PAH
(28), although V106A additionally showed a distinct peak of
aggregates (Fig. 2A). Blue native polyacrylamide gel electro-
phoresis (BN-PAGE) showed tetramers, dimers and monomers
in an apparent equilibrium for wild-type and variant PAH,
with V106A displaying more high-molecular-weight aggre-
gates and a higher amount of degradation fragments than the
wild-type (Fig. 2B). Subsequent analyses focussed on the
active enzyme homo-oligomer obtained by the separation of
the tetrameric SEC fraction. The determination of particle
sizes by dynamic light scattering (DLS) at the steady state
revealed two populations for the wild-type corresponding to
native-state protein and soluble aggregates in equilibrium.
For V106A, a shift towards the non-native state was observed
(Fig. 2C). Analysis of kinetics of soluble aggregate formation
over time resulted in a significantly (P ¼ 0.0037) higher expo-
nential growth rate constant for V106A (k ¼ 0.072) than for
the wild-type (k ¼ 0.041) (Fig. 2D).
Differential scanning fluorimetry (DSF) showed increased
ground state hydrophobicity of V106A in comparison to the
wild-type, indicating the presentation of non-native state
hydrophobic groups at the protein surface. Thermal unfolding
disclosed a two-phase transition from native to the unfolded
state for wild-type and V106A. This corresponds to human
PAH, where the first transition reflects unfolding of the regu-
latory and the second unfolding of the catalytic domain (4,29)
(Fig. 2E). Although the shape and total height of the curves
differed, midpoints of the first and second transitions were
similar for wild-type and V106A.
The impact of local unfolding on protein stability as well as
the equilibrium between native-state oligomeric protein and
potential folding intermediates was further analyzed by
limited proteolysis (30,31). Compared with the wild-type,
V106A revealed degradation bands even without the addition
of proteinase K and showed a different fragmentation pattern
(Fig. 2F). The half-life of the intact PAH band (52 kDa)
after the proteolytic cleavage of the MBP fusion partner was
prolonged for V106A (34 min) in comparison to the wild-type
(13 min). This finding may be explained by the fact that aggre-
gates not attacked by proteinase K could appear as intact PAH
in a denaturating SDS–PAGE.
Taken together, the equilibrium of native-state and partially
unfolded or misfolded protein is shifted towards a distorted
V106A conformation, explaining proneness to aggregation
and susceptibility to degradation.
BH4 rescues loss of function in vivo
We showed that Pahenu1 has the same pathophysiological
background of protein misfolding with loss of function as
that associated with human PAH mutations (4,14,16). We
Figure 2. Impact of the V106A mutation on PAH protein conformation
in vitro. Wild-type (WT) and V106A-PAH were expressed as fusion protein
to MBP, purified by affinity chromatography and tetrameric MBP–PAH
was separated by SEC. (A) Oligomerization profiles (normalized to tetrameric
WT) determined by SEC. Arrows indicate soluble aggregates (A, 120 ml), tet-
ramers (T, 140 ml) and dimers (D, 158 ml). (B) BN-PAGE analysis of affinity-
purified protein. Arrows indicate aggregates (A), tetramers (T, 380 kDa),
dimers (D, 190 kDa), monomers (M, 95 kDa) and degradation fragments
(F). (C) Particle size distribution of the tetrameric SEC fraction determined
by DLS. The cumulative relative occurrences (relative intensity, y-axis) of par-
ticles with distinct effective diameters (x-axis) of n ¼ 3 independent exper-
iments are shown. Expected diameter for tetrameric MBP–PAH is 16 nm.
(D) Aggregation kinetics measured by DLS. The rate constants (k) of
changes in the effective diameter of the protein are given and the significance
is indicated (∗∗P , 0.01). Data points represent means+ s.e.m. of n ¼ 3
experiments. (E) Thermal denaturation analyzed by DSF. Data points rep-
resent means+ s.e.m. of n ¼ 3 experiments. The inset shows the fluorescence
at 308C normalized to WT. (F) Proteolytic degradation patterns of MBP–PAH
fusion proteins. Samples were incubated without proteinase K (N) or for
5–120 min at 378C with proteinase K. Fusion proteins (FP), the cleaved-off
PAH protein (PAH) and proteolytic fragments of PAH were detected. One
representative experiment out of four is shown for WT and V106A.
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now aimed to analyze whether the pharmacological chaperone
BH4 corrects these alterations. In our wild-type mice, one
single dose of 10 mg/g body weight (bw), commonly used in
the treatment of PAH-deficient patients, led to a liver peak
concentration of 43 mmol/l BH4 30 min after injection.
Hence, this concentration was used for the following exper-
iments in cell culture and in vitro.
The effect of BH4 on PAH protein amount and enzyme
activity was first characterized after transient expression of
wild-type and V106A-PAH in COS-7 cells (Fig. 3A). Treat-
ment with BH4 at low phenylalanine concentrations
(96 mmol/l in the medium) did not result in a rise of protein
amount or enzyme activity in wild-type or V106A. Notably,
pathologically high phenylalanine concentrations (1 mM) pro-
duced a mild increase in the amount of wild-type and, more
pronounced, of the V106A-PAH protein. However, this had
no perceptible effect on enzyme activity. Only the application
of BH4 at high phenylalanine concentrations resulted in a sig-
nificant increase in V106A-PAH protein amount (P, 0.01)
and activity (P , 0.05), suggesting that the pharmacological
chaperone exerts its action predominantly at harmful substrate
levels.
BH4 treatment in vivo (2 × 10 mg/g bw × d, 3 days) signifi-
cantly (P , 0.01) lowered blood phenylalanine concentrations
(median, 396–139 mmol/l) in Pahenu1, while the wild-type
remained at physiological levels (median, 68 mmol/l)
(Fig. 3B). The therapeutic effect of BH4 on hyperphenylalani-
nemia was functionally confirmed by placebo-controlled
13C-phenylalanine oxidation tests, demonstrating rescue of
in vivo PAH activity. Treatment normalized 13CO2 recovery
in Pahenu1 to wild-type levels, whereas it had no effect in
Pahenu2 (Fig. 3C). This was attended by a significant increase
in liver PAH protein in the wild-type (P, 0.01) and, even
more pronounced, in Pahenu1 (P , 0.001) (Fig. 3D).
These data show that BH4 corrects the biochemical pheno-
type of Pahenu1 through stabilization of the PAH protein
in vivo. Moreover, the pharmacological chaperone-mediated
rescue of enzyme function requires an imbalanced metabolic
state reflected by hyperphenylalaninemia and sufficient
specific residual enzyme activity.
BH4 corrects protein misfolding
To dissect the molecular mode of action of the pharmacologi-
cal chaperone BH4 at the protein level, we analyzed its effect
on PAH misfolding/unfolding, aggregation and degradation.
The addition of BH4 (43 mM) significantly (P , 0.01)
reduced the increased hydrophobicity of recombinant
V106A, while it had no effect on the wild-type protein
(Fig. 4A). Native-state stabilization with respect to the
Figure 3. BH4 stabilizes the PAH protein and corrects loss of function in vivo. (A) Wild-type (WT) and V106A-PAH proteins were overexpressed in COS-7 cells
for 72 h and cultured in basic medium (RPMI 1640, L-phenylalanine 96 mM; control). The medium was supplemented with either BH4 (43 mM), additional
L-phenylalanine (final concentration 1 mM) or both BH4 and L-phenylalanine as indicated. Data were normalized to the control and significances relative to
the control are indicated (∗P, 0.05, ∗∗P , 0.01). Bars represent means+ s.e.m. of n ¼ 5 experiments. (B) Basic blood phenylalanine levels before and
after BH4 therapy. Wild-type (WT) and Pah
enu1 (ENU1) mice were treated with either 20 mg BH4/g bw or placebo for 3 days in two single doses per day.
Box plots represent blood phenylalanine levels of n ¼ 4 (WT) and n ¼ 7 (ENU1) animals and the significance is indicated (∗∗P, 0.01). (C) Phenylalanine
oxidation rates determined by a 13C-phenylalanine breath test. Mice were treated with BH4 (20 mg/g bw) or placebo and the cumulative CO2 recovery was mon-
itored in n ¼ 6 animals for each genotype and is given as mean values+ s.e.m. (D) Relative amounts of PAH protein in liver lysates after treatment with BH4
(20 mg/g bw for 3 days). Data were normalized to mice that received placebo and are given as means+ s.e.m. of n ¼ 3 experiments. ∗∗P , 0.01, ∗∗∗P , 0.001.
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midpoint of unfolding (Tm) was observed upon application of
thermal stress (wild-type, 38.96–44.158C, P ¼ 0.042; V106A,
40.39–42.018C, P ¼ 0.184). BH4 induced a right shift of the
low-temperature transition, indicating stabilization of the
regulatory domain of the proteins, which was more pro-
nounced in the wild-type (Fig. 4B). The minor effect for
Figure 4. BH4 prevents PAH aggregation and degradation. (A) Relative hydrophobicity of wild-type (WT) and V106A-PAH proteins determined by ANS flu-
orescence at 258C with and without the addition of BH4 (43 mM). Plots represent ANS-fluorescence values normalized to WT without BH4 of n ¼ 4 experiments
and the significance is indicated (∗∗P , 0.01). (B) Thermal unfolding of wild-type (WT) and V106A-PAH with and without the addition of BH4 (43 mM) mon-
itored by ANS fluorescence. The fractions of unfolded PAH protein are plotted as a function of increasing temperatures. Data points represent the mean+ s.e.m.
of n ¼ 3 experiments. (C) Temperature-induced aggregation of wild-type (WT) and V106A-PAH observed by RALS. Aggregate formation in the presence or
absence of BH4 (43 mM) and L-phenylalanine (1 mM) was detected. For the linear phase of aggregation, the transition midpoints and the slopes of the curves were
calculated by linear regression analysis (Table 3). The insets depict the slopes at the linear phase of aggregation. Data points and calculated values represent
means+ s.e.m. of n ¼ 3 experiments. (D) Aggregation of WT and V106-PAH protein expressed in COS-7 cells upon treatment with BH4 (43 mM) and/or
L-phenylalanine (1 mM). The PAH amount in the soluble and pellet fractions was detected. Bars are normalized to the soluble fraction and represent
means+ s.e.m. of n ¼ 4 experiments. (E) Protection against degradation-induced loss of PAH function in a eukaryotic TnT system. Wild-type (WT) and
V106A-PAH were expressed with or without the addition of BH4 (500 mM) and L-phenylalanine (1 mM) as indicated. The reaction was stopped and the relative
activity was assessed following further incubation for 0, 1 or 2 h at 378C. Significances of changes in relation to the control (no BH4/L-phenylalanine) are indi-
cated (∗∗∗P , 0.001). Data are normalized to wild-type activity at time point 0 and bars represent means+ s.e.m. of n ¼ 3 experiments.
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V106A may be attributed to a conformational rearrangement
of the regulatory domain due to the variant enzyme’s pre-
activation (Table 2).
Protein aggregate formation upon thermal stress was
assessed by right angle light scattering (RALS). Without addi-
tives, aggregation occurred in the range between 50 and 608C
and reached a plateau at 608C (Fig. 4C). Addition of the cofac-
tor BH4 led to aggregation at lower temperatures, whereas
pathological concentrations of the substrate L-phenylalanine
(1 mM) led to aggregation at higher temperatures for wild-type
and V106A (Table 3). Neither phenylalanine nor BH4,
however, markedly changed the slope of the curves when
applied alone. Only the combined application of BH4 and
phenylalanine substantially reduced aggregation rates, with a
more pronounced effect in V106A (slope reduced to 14.7%
of initial) than in the wild-type (32.7% of initial).
These results were substantiated at the cellular level. In
transiently transfected COS-7 cells, wild-type PAH was predo-
minantly found in the soluble fraction with ,20% of the
protein in the pellet (Fig. 4D). V106A, though, accumulated
in the pellet fraction, indicating enhanced aggregation
in vivo. Supplementation of the medium with BH4 or phenyl-
alanine (1 mM) moderately reduced variant PAH in the pellet.
However, a combined application of BH4 and phenylalanine
markedly decreased aggregation. We then investigated the
impact of the pharmacological chaperone BH4 on PAH
activity over time in a eukaryotic TnT system (Fig. 4E). In
the absence of BH4 and phenylalanine, wild-type and
V106A activity declined within 1 h, where the initial activity
of V106A was lower than that of the wild-type and decreased
more rapidly. In the presence of BH4 and phenylalanine, loss
of wild-type and V106A activity was reverted and V106A
reached wild-type levels. The initial reduction of wild-type
activity upon addition of BH4 is in line with the inhibitory
effect of BH4 observed in the phenylalanine oxidation tests
(Fig. 3C) and reflects the well-known cofactor inhibition of
PAH activity (32–34).
In conclusion, BH4 exerts its effect as a pharmacological
chaperone in the Pahenu1 mouse by stabilization of PAH con-
formation and thus preventing aggregation and protecting the
mutant enzyme from rapid degradation.
DISCUSSION
The relevance of protein misfolding for inherited diseases is
increasingly appreciated and novel therapeutic strategies
emerge. A substantial number of small-molecule chemical
compounds, which either stabilize the distorted protein confor-
mation or restore the function of affected biological pathways,
were lately identified (Supplementary Material, Table S1)
(7,9–11). One of these is BH4, recently approved by the
FDA and the EMEA as an orphan drug to correct protein mis-
folding in PAH deficiency. This makes BH4 the first represen-
tative of a new class of pharmaceutical drugs, and further
stabilizing compounds for other diseases are likely to follow.
Here, we report that the Pahenu1 mouse shows BH4-
responsive PAH deficiency and therefore is a model for a trea-
table protein misfolding disease with loss of function.
Although Pahenu1 displays a biochemical phenotype, the
specific PAH activity is normal. We identified loss of PAH
protein as a cause of loss of function in this animal model.
It is a consequence of misfolding and accelerated degradation
of the enzyme. Notably, our in vitro and in vivo data revealed
that aggregation also significantly contributes to loss of func-
tion. The elucidation of this triad created the basis to dissect
the molecular mode of action of the pharmacological chaper-
one BH4 bridging in vitro data on protein stabilization to
in vivo metabolic state and enzyme activity.
The PAH protein is a flexible, highly regulated tetrameric
enzyme undergoing conformational changes upon binding of
the L-phenylalanine substrate and the natural cofactor BH4
(35–37). The latter functions as a negative effector to form
a dead-end PAH–BH4 complex in vivo. This keeps the
enzyme in an inactivated form that is activated by high
blood phenylalanine concentrations (38). As previously
described for human mutations (4,16), the genetic alteration
in this mouse does not lead to changes in PAH affinity to
the cofactor or to a marked reduction of specific enzyme
activity. Thus, the mode of action of BH4 in PAH deficiency
is not related to its cofactor action. Instead, pharmacological
doses of BH4 lead to protein stabilization augmenting the
effective PAH concentration, that is, the amount of correctly
folded and functional PAH. This is achieved by decelerating
aggregation, reducing protein hydrophobicity and slowing-
down degradation. At a structural-mechanistic level, the
improved biochemical phenotype is the result of a trade-off
between a gain in protein rigidity and a loss of enzyme
activity. Whereas wild-type mice display a drug-induced
decrease in PAH activity, in Pahenu1 the increase in effective
enzyme concentration overrules the inhibition by BH4 and
thus explains complete correction of enzyme activity in vivo.
Hence, the chemical compound has a direct influence on
PAH protein chemistry, shifting the activated, instable and
aggregation-prone conformation towards a less active but
stabilized state.
We observed that BH4 was very effective at high phenyl-
alanine concentrations, whereas it did not increase enzyme
activity at low substrate levels. This phenomenon of selective
pharmaceutical action adjusted to metabolic needs can be
ascribed to the complex regulation of the phenylalanine hydro-
xylating system known from human and rat PAH (32–34,39),
and here confirmed to be analogous in the mouse. The physio-
Table 3. Parameters of aggregation kinetics assessed by RALS
WT V106A
Tm1/2 (8C) Slope Tm1/2 (8C) Slope
No BH4/L-Phe 57.20+0.07 55.31+3.46 58.95+0.09 27.24+4.07
43 mM BH4 54.54+0.03 69.44+3.92 55.85+0.06 30.19+1.95
1 mM L-Phe 58.76+0.05 54.54+2.22 60.29+0.06 31.64+1.99
43 mM BH4 /
1 mM
L-Phe
57.14+0.06 18.09+0.68 59.09+0.10 4.00+0.17
Temperature induced aggregation of wild-type (WT) and V106A-PAH
observed by RALS. Aggregate formation in the presence or absence of 43 mM
BH4 and 1 mM L-phenylalanine was detected. Transition midpoints (Tm1/2)
defined as the temperature at half-maximum aggregation were calculated by
nonlinear regression analysis using the Boltzman sigmoidal equation. For the
linear phase of aggregation, the slopes of the curves were calculated by linear
regression analysis. Values represent means+ s.e.m. of n ¼ 3 experiments.
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logical inhibitory action of the cofactor BH4 is reflected in the
pharmacological inoperativeness of the drug at low substrate
concentrations. This is of particular importance since it pre-
vents undue elimination of the essential amino acid phenyl-
alanine and thus protects the patient from overtreatment.
This makes BH4 a pharmacological chaperone drug with the
ideal characteristic of an integrated self-limiting mechanism
considerably improving its safety profile.
The animal model described here will allow for studies
leading to significant advances for patients with PKU. It will
enable further pharmacological studies that address detailed
pharmacodynamics and pharmacokinetics of BH4 in a mouse
displaying the disease-specific phenotype, and it will provide
valuable information towards individually tailored treatment
strategies by its use to explore BH4 dosing at various meta-
bolic states. Moreover, an in vivo model will be mandatory
for the development of optimized BH4 derivatives and future
generations of PAH stabilizing compounds (40) with improved
bioavailability and efficacy.
However, the use of Pahenu1 will not be confined to issues
related to PAH. Direct analyses of the misfolded protein’s
function (in vivo enzyme activity) and the biochemical pheno-
type (metabolite concentrations) in the living animal offer the
opportunity to investigate universal cellular pathways modu-
lating loss-of-function pathology. These will include the con-
certed action of molecular chaperones, the unfolded protein
response pathway, and the protein degradation machinery.
Moreover, the impact of epigenetic and environmental stress
factors, such as single nucleotide polymorphisms, oxidative
stress, or fever, which trigger or exacerbate conformational
diseases, can be analyzed. Finally, the model may be used to
explore the efficacy of alternative compounds or combinatorial
therapeutic strategies, where pharmacological chaperones act
in synergy with antioxidative substances, proteasome inhibi-
tors or regulators of protein homeostasis (7,11).
In conclusion, our data support a general model of pharma-
cological chaperone-induced stabilization of protein confor-
mation to correct protein misfolding with loss of function.
The knowledge gained and the experimental strategies
applied will be applicable to other maladies belonging to
this group of disorders and may thus promote the development
of new drugs for the treatment of misfolding-associated
genetic and non-genetic diseases.
MATERIALS AND METHODS
Plasmid constructs and site-directed mutagenesis
The cDNA of murine Pah (EST clone from imaGenes) was
cloned into the pcDNA3.1/myc-His C vector (Invitrogen).
The mutations V106A and F263S were introduced into the
pcDNA3.1 plasmid using the PCR-based QuikChange site-
directed mutagenesis kit (Stratagene) and authenticity was ver-
ified by DNA sequencing. Subsequently, wild-type and mutant
cDNAs were subcloned into the prokaryotic expression vector
pMAL-c2E (New England Biolabs) or the eukaryotic
expression vector pEF-DEST51 (Invitrogen). In order to
create constructs for eukaryotic expression of wild-type and
variant PAH, the Gateway technology (Invitrogen) was used.
Genes were amplified using primers containing flanking attB
sites, Kozak sequence at the 5′ terminus (MmPah forward)
and a stop codon at the 3′ terminus (MmPah reverse) (Sup-
plementary Material, Table S2). Obtained PCR products
were subsequently cloned into the pEF-DEST51 vector carry-
ing the human elongation factor promotor (Invitrogen), fol-
lowing the manufacturer’s protocols.
Protein expression and purification
Expression plasmids were transformed into E. coli DH5a.
Wild-type and variant fusion proteins (MBP–PAH) were
overexpressed for 20 h at 378C as described previously (4).
Proteins were purified on A¨KTAxpress (GE Healthcare) at
48C by loading crude extracts on a MBPTrap affinity chrom-
atography column (GE Healthcare) equilibrated with column
buffer (20 mM Tris–HCl, 200 mM NaCl, pH 7.4) and by
elution with the same buffer supplemented with 10 mM
maltose.
PAH activity assay
PAH activity was determined as described previously (27,41)
with various modifications (4). Recombinant tetrameric PAH
(0.01 mg/ml) was pre-incubated with L-Phe and catalase
(1 mg/ml) for 5 min (258C) in 15 mM Na HEPES, pH 7.3, fol-
lowed by 1 min incubation with 10 mM ferrous ammonium
sulfate. The reaction was initiated by the addition of
6[R]-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4, Schircks
Laboratories) stabilized in 2 mM DTT, carried out for 1 min
and stopped by acetic acid, followed by 10 min incubation
at 958C. Kinetic parameters were determined at standard
L-Phe (1 mM) and BH4 (75 mM) concentrations at variable
BH4 (0–704.1 mM) or L-Phe (0–4.5 mM) concentrations,
respectively. To determine the level of substrate activation,
pre-incubation with the substrate was omitted and the reaction
was triggered by simultaneous addition of 1 mM L-Phe and
75 mM BH4 (activation fold). All concentrations mentioned
refer to the final concentration in a 100 ml reaction mixture.
The amount of the product (L-tyrosine) was measured by
HPLC and assayed as triplicates. In the case of PAH obtained
from either cell culture or the TnT system, 20 ml of total
lysates were used for the activity assay. The reaction initiated
by the addition of BH4 was carried out for 60 min (cell culture
and TnT) or 20 min (liver lysates), respectively. Steady-state
kinetic parameters of three independent experiments were cal-
culated by nonlinear regression analysis with the use of Graph-
Pad Prism 4.0c (GraphPad Software). Enzyme kinetic
parameters at variable substrate concentrations displayed
cooperativity and were calculated with the Hill equation.
Enzyme kinetic parameters at variable cofactor concentrations
were calculated with the Michaelis–Menten equation. All
experimental data were confirmed by repeated analyses of
different protein purifications.
Analysis of oligomerization
Oligomerization profiles were obtained by SEC on a HiLoad
26/60 Superdex 200 column (GE Healthcare) equilibrated
with SEC buffer (20 mM Na HEPES, 200 mM NaCl, pH 7.0)
and relative amounts of the different oligomeric states were
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calculated as described previously (4). Protein concentrations
were determined spectrophotometrically with the use of the
absorption coefficient A280 or the Bradford assay. All follow-
ing experiments using recombinant protein, except for the
BN-PAGE analysis, were performed with tetrameric fusion
proteins.
Blue native polyacrylamide gel electrophoresis
BN-PAGE was used to analyze non-dissociated protein com-
plexes with respect to composition, oligomeric state and mol-
ecular mass. For this purpose, the protein pool of
affinity-purified wild-type mouse PAH was separated via
native PAGE using 4–16% (w/v) pre-cast polyacrylamide-
gradient native gels in a Bis–Tris buffer system (Invitrogen).
The electrophoresis was started at 150 V for 60 min and contin-
ued for 90 min at 250 V at 48C. Following BN-PAGE, proteins
were denatured in the gel, stained with Coomassie Brilliant
Blue R-250 (Bio-Rad) and the oligomeric state was determined
in comparison to protein standards (GE Healthcare).
SDS–PAGE and immunoblotting
The proteins were separated by 4–12% gradient polyacryl-
amide gels (Invitrogen) and blotted onto a nitrocellulose mem-
brane (Schleicher & Schuell BA-S 85). The membrane was
blocked with 5% milk in 1× TBS followed by 1 h of incu-
bation with the primary antibody, mouse monoclonal
anti-PAH PH8 (Calbiochem, 1 : 1000 dilution), and 1 h of
incubation with the secondary antibody, anti-mouse IgG con-
jugated with alkaline phosphatase (Promega, 1 : 7500
dilution). Blots were visualized with CDP-Star substrate
(Roche) and chemiluminescence was monitored with a
DIANA III imaging system, and the resulting protein bands
were quantified by AIDA software (Raytest).
Dynamic light scattering
DLS analysis was performed on a ZetaPALS particle size ana-
lyzer (Brookhaven Instruments Corporation) equipped with a
precision Peltier temperature control unit. The steady-state
determination of particle sizes of the tetrameric fusion proteins
MBP–PAH (10 mM PAH subunit) diluted in SEC buffer was
performed at 25 8C at time intervals of 1 min over a period
of 10 min in six independent measurements. The kinetics of
thermal aggregation over time was monitored at 528C at
time intervals of 1 min until the precipitation of insoluble
aggregates. Analysis of three independent experiments was
performed by fitting the obtained data to a single exponential
growth curve. The scattering angle was 908.
Limited proteolysis by proteinase K
Experiments were performed as described previously (4).
Wild-type and V106A murine MBP–PAH were digested
with proteinase K (substrate to protease ratio 1 : 5000) at
378C in SEC buffer. SDS–PAGE electrophoresis and immu-
noblotting with anti-PAH antibody were performed and the
resulting PAH bands were quantified by AIDA software
(Raytest).
Thermal denaturation assays
RALS and DSF analyses were performed on a Cary Eclipse
fluorescence spectrophotometer equipped with a temperature-
controlled Peltier multicell holder (Varian). Denaturation of
protein samples diluted in SEC buffer containing 1 mM DTT
was performed by scanning a temperature range of 25–858C
at a rate of 1.28C/min (25–358C and 75–858C) or 0.28C/
min (35–758C). In the cases indicated, L-phenylalanine
(Sigma) and BH4 were added to final concentrations of
1 mM and 43 mM, respectively. In DSF experiments, the
changes in 8-anilino-1-naphtalenesulfonic acid (ANS, Sigma
Aldrich) fluorescence emission at 500 nm (excitation
395 nm, slit widths 5.0/10.0 nm) were monitored. Data analy-
sis was performed by fitting the experimental curves as
described previously (40). The phase transitions of three inde-
pendent experiments were determined and the respective tran-
sition midpoints were calculated by differentiation of the
increasing part of the curves. We previously showed that the
denaturation of MBP did not interfere with the unfolding
curves of the PAH protein for ANS fluorescence (4). Protein
aggregation based on hydrophobic self-association was deter-
mined by RALS. The intensity of scattered light at 335 nm
was detected in the right angle to the excitation light of
330 nm upon thermal denaturation of MBP–PAH (0.8 mM
PAH subunit). Data points were analyzed by the Boltzman sig-
moidal equation for the transition temperatures and the first-
order straight-line exponential equation for the slope.
Coupled in vitro transcription–translation of PAH
In vitro transcription and translation (TnT) of mouse PAH was
carried out using the pcDNA3.1 constructs and the TnT-T7
reticulocyte lysate system (Promega). The TnT reaction was
performed for 90 min in the absence or presence of 500 mM
BH4 and 1 mM L-Phe in 2 mM DTT. After stopping the reaction
by DNase A and RNase A, the lysates were further incubated
at 378C and aliquots were taken at indicated time points. For
PAH activity assays, free amino acids were removed by
microcon centrifugal filters (Millipore).
Transient expression of PAH in COS-7
COS-7 cells were maintained in basic RPMI 1640 medium
(96 mM L-phenylalanine) with stable glutamine supplemented
with 10% fetal bovine serum and 1% antibiotics (PAA). For
transient expression of wild-type and V106A-PAH, the
pEF-DEST51 cDNA constructs were used. After transfection
with 3 mg DNA per 1 million cells using the Amaxa electro-
poration system (Lonza), cells were cultured for 72 h under
three different conditions: (i) basic medium (as described
above), (ii) basic medium supplemented with 43 mM BH4
and 5 mg/ml ascorbic acid (Fluka), (iii) basic medium with
43 mM BH4, 5 mg/ml ascorbic acid and 1 mM L-Phe. Culture
medium was changed every 24 h. Cells were harvested by
scraping and lysed by three freeze–thaw cycles in a lysis
buffer (SEC buffer containing 1% Triton X-100 and proteinase
inhibitors), followed by 20 min centrifugation at 14 000 rpm at
48C. Both recovered supernatants and pellets resuspended
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in lysis buffer were kept at 2808C until being used for SDS–
PAGE/immunoblotting and activity assays.
In vivo animal studies
Wild-type (BTBR T+tf/J), Pahenu1 (BTBR.Cg-Pahenu1/J) and
Pahenu2 (BTBR-Pahenu2/J) mice were purchased from The
Jackson Laboratory and kept under standard conditions.
Mouse studies were approved by the Austrian Animal Care
and Use Committee in accordance with national and inter-
national laws and standards for animal protection. Animals
were housed in a controlled temperature room maintained
under alternating 12 h light and dark cycles and, in between
experiments, had free access to food and water. While
Pahenu1 and wild-type mice were fed with standard breeder
mouse chow (UIZ, Knittelfeld, Austria), Pahenu2 mice were
kept euphenylalaninemic with a diet devoid of phenylalanine
(Teklad 97152) and water containing 30 mg L-phenylalanine.
They were placed on standard chow 3 days before the exper-
iments to produce a hyperphenylalaninemic state. The effect
of BH4 (20 mg/g bw b.i.d. by intraperitoneal injection for
3 days) or placebo (NaCl 0.9%, ascorbic acid 0.2%) was
assessed on blood phenylalanine concentrations and on
in vivo phenylalanine oxidation. For this purpose, breath
tests were performed in conscious mice. After the i.p. appli-
cation of 13C-labeled L-phenylalanine (15 mg/g bw, Euriso-
top), the mice were placed in individual 100 ml breath
chambers with a continuous flow of CO2-free air for
105 min and breath samples were collected in 6.5 min inter-
vals. For each of the samples, the airflow was discontinued
to allow CO2 levels to accumulate above the limit of quantifi-
cation (0.8%). At the end of accumulation, the sample was
insufflated into an infrared spectrometer (IRIS Wagner Analy-
sen Technik, Germany) for online isotope analysis. The cumu-
lative recovery of 13C in breath samples was calculated based
on the 13CO2/
12CO2 ratio assuming a total CO2 production rate
of 94 ml/min per g bw × m2 body surface area. The amount of
labeled CO2 formed was expressed as the cumulative percen-
tage of the dose administered as a function of time. Blood
samples for the determination of blood phenylalanine concen-
trations were collected immediately before the breath test and
spotted to filter cards. Then, 3.2 mm spots of these samples
were extracted with 200 ml of methanol (containing internal
standard) and analyzed by electrospray ionization tandem
mass spectrometry. For assessment of PAH activity and
PAH protein amount, mice were sacrificed by cervical dislo-
cation 1 h after the last dosage. Liver samples were collected
and processed immediately. The liver tissue was homogenized
and lysed in a buffer containing 200 mM KCl, 30 mM Tris–
HCl, pH 7.25, and proteinase inhibitors. Samples were then
centrifuged for 50 min at 48C and 14 000 rpm and resulting
supernatants were frozen in liquid nitrogen until being used
for SDS–PAGE/immunoblotting and activity assays. Protein
concentration was determined using the Bradford assay.
Statistical analyses
Group mean values were compared by Student’s unpaired
two-tailed t test, and one-way analysis of variance with
Dunnett’s post hoc test was applied for multiple comparisons.
Statistical analyses were performed using GraphPad Prism
4.0c (GraphPad Software).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
ACKNOWLEDGEMENTS
We wish to thank Anja Schultze, Heike Preisler, Bernadette
Schmidt, Maria Trieb and Susanne Wullinger for excellent
technical assistance and Georg Wietzorrek for assistance
with animal husbandry and animal experiments. This article
is part of an M.D. thesis to be submitted by A.E. at
Ludwig-Maximilians-University, Munich, Germany.
Conflict of Interest statement. None declared.
FUNDING
This work was supported by the Bavarian Genome Research
Network (BayGene) and by the Dr Legerlotz-Stiftung Liech-
tenstein.
REFERENCES
1. Selkoe, D.J. (2004) Cell biology of protein misfolding: the examples of
Alzheimer’s and Parkinson’s diseases. Nat. Cell Biol., 6, 1054–1061.
2. Soto, C. (2003) Unfolding the role of protein misfolding in
neurodegenerative diseases. Nat. Rev. Neurosci., 4, 49–60.
3. Winklhofer, K.F., Tatzelt, J. and Haass, C. (2008) The two faces of
protein misfolding: gain- and loss-of-function in neurodegenerative
diseases. EMBO J., 27, 336–349.
4. Gersting, S.W., Kemter, K.F., Staudigl, M., Messing, D.D., Danecka,
M.K., Lagler, F.B., Sommerhoff, C.P., Roscher, A.A. and Muntau, A.C.
(2008) Loss of function in phenylketonuria is caused by impaired
molecular motions and conformational instability. Am. J. Hum. Genet., 83,
5–17.
5. Conn, P.M., Ulloa-Aguirre, A., Ito, J. and Janovick, J.A. (2007) G
protein-coupled receptor trafficking in health and disease: lessons learned
to prepare for therapeutic mutant rescue in vivo. Pharmacol. Rev., 59,
225–250.
6. Balch, W.E., Morimoto, R.I., Dillin, A. and Kelly, J.W. (2008) Adapting
proteostasis for disease intervention. Science, 319, 916–919.
7. Mu, T.W., Ong, D.S., Wang, Y.J., Balch, W.E., Yates, J.R. 3rd, Segatori,
L. and Kelly, J.W. (2008) Chemical and biological approaches synergize
to ameliorate protein-folding diseases. Cell, 134, 769–781.
8. Gregersen, N., Bross, P., Vang, S. and Christensen, J.H. (2006) Protein
misfolding and human disease. Annu. Rev. Genomics Hum. Genet., 7,
103–124.
9. Cohen, F.E. and Kelly, J.W. (2003) Therapeutic approaches to
protein-misfolding diseases. Nature, 426, 905–909.
10. Conn, P.M. and Janovick, J.A. (2009) Drug development and the cellular
quality control system. Trends Pharmacol. Sci., 30, 228–233.
11. Powers, E.T., Morimoto, R.I., Dillin, A., Kelly, J.W. and Balch, W.E.
(2009) Biological and chemical approaches to diseases of proteostasis
deficiency. Annu. Rev. Biochem., 78, 959–991.
12. Muntau, A.C., Ro¨schinger, W., Habich, M., Demmelmair, H., Hoffmann,
B., Sommerhoff, C.P. and Roscher, A.A. (2002) Tetrahydrobiopterin as an
alternative treatment for mild phenylketonuria. N. Engl. J. Med., 347,
2122–2132.
13. Aguado, C., Perez, B., Ugarte, M. and Desviat, L.R. (2006) Analysis of
the effect of tetrahydrobiopterin on PAH gene expression in hepatoma
cells. FEBS Lett., 580, 1697–1701.
14. Erlandsen, H., Pey, A.L., Gamez, A., Perez, B., Desviat, L.R., Aguado, C.,
Koch, R., Surendran, S., Tyring, S., Matalon, R. et al. (2004) Correction
2048 Human Molecular Genetics, 2010, Vol. 19, No. 10
of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria
patients with certain phenylalanine hydroxylase mutations. Proc. Natl
Acad. Sci. USA, 101, 16903–16908.
15. Perez, B., Desviat, L.R., Gomez-Puertas, P., Martinez, A., Stevens, R.C.
and Ugarte, M. (2005) Kinetic and stability analysis of PKU mutations
identified in BH4-responsive patients. Mol. Genet. Metab., 86 (Suppl. 1),
S11–S16.
16. Pey, A.L., Perez, B., Desviat, L.R., Martinez, M.A., Aguado, C.,
Erlandsen, H., Gamez, A., Stevens, R.C., Thorolfsson, M., Ugarte, M.
et al. (2004) Mechanisms underlying responsiveness to
tetrahydrobiopterin in mild phenylketonuria mutations. Hum. Mutat., 24,
388–399.
17. Kure, S., Sato, K., Fujii, K., Aoki, Y., Suzuki, Y., Kato, S. and Matsubara,
Y. (2004) Wild-type phenylalanine hydroxylase activity is enhanced by
tetrahydrobiopterin supplementation in vivo: an implication for
therapeutic basis of tetrahydrobiopterin-responsive phenylalanine
hydroxylase deficiency. Mol. Genet. Metab., 83, 150–156.
18. Scavelli, R., Ding, Z., Blau, N., Haavik, J., Martinez, A. and Thony, B.
(2005) Stimulation of hepatic phenylalanine hydroxylase activity but not
Pah-mRNA expression upon oral loading of tetrahydrobiopterin in normal
mice. Mol. Genet. Metab., 86 (Suppl. 1), S153–S155.
19. Tho¨ny, B., Ding, Z. and Martinez, A. (2004) Tetrahydrobiopterin protects
phenylalanine hydroxylase activity in vivo: implications for
tetrahydrobiopterin-responsive hyperphenylalaninemia. FEBS Lett., 577,
507–511.
20. McDonald, J.D. and Charlton, C.K. (1997) Characterization of mutations
at the mouse phenylalanine hydroxylase locus. Genomics, 39, 402–405.
21. McDonald, J.D., Bode, V.C., Dove, W.F. and Shedlovsky, A. (1990)
Pahhph-5: a mouse mutant deficient in phenylalanine hydroxylase. Proc.
Natl Acad. Sci. USA, 87, 1965–1967.
22. Sarkissian, C.N., Boulais, D.M., McDonald, J.D. and Scriver, C.R. (2000)
A heteroallelic mutant mouse model: a new orthologue for human
hyperphenylalaninemia. Mol. Genet. Metab., 69, 188–194.
23. Shedlovsky, A., McDonald, J.D., Symula, D. and Dove, W.F. (1993)
Mouse models of human phenylketonuria. Genetics, 134, 1205–1210.
24. McDonald, J.D., Andriolo, M., Cali, F., Mirisola, M., Puglisi-Allegra, S.,
Romano, V., Sarkissian, C.N. and Smith, C.B. (2002) The
phenylketonuria mouse model: a meeting review. Mol. Genet. Metab., 76,
256–261.
25. Ledley, F.D., Grenett, H.E., Dunbar, B.S. and Woo, S.L. (1990) Mouse
phenylalanine hydroxylase. Homology and divergence from human
phenylalanine hydroxylase. Biochem. J., 267, 399–405.
26. Treacy, E.P., Delente, J.J., Elkas, G., Carter, K., Lambert, M., Waters, P.J.
and Scriver, C.R. (1997) Analysis of phenylalanine hydroxylase
genotypes and hyperphenylalaninemia phenotypes using
L-[1-13C]phenylalanine oxidation rates in vivo: a pilot study. Pediatr.
Res., 42, 430–435.
27. Martinez, A., Knappskog, P.M., Olafsdottir, S., Doskeland, A.P., Eiken,
H.G., Svebak, R.M., Bozzini, M., Apold, J. and Flatmark, T. (1995)
Expression of recombinant human phenylalanine hydroxylase as fusion
protein in Escherichia coli circumvents proteolytic degradation by host
cell proteases. Isolation and characterization of the wild-type enzyme.
Biochem. J., 306 (Pt 2), 589–597.
28. Kappock, T.J., Harkins, P.C., Friedenberg, S. and Caradonna, J.P. (1995)
Spectroscopic and kinetic properties of unphosphorylated rat hepatic
phenylalanine hydroxylase expressed in Escherichia coli. Comparison of
resting and activated states. J. Biol. Chem., 270, 30532–30544.
29. Thorolfsson, M., Ibarra-Molero, B., Fojan, P., Petersen, S.B.,
Sanchez-Ruiz, J.M. and Martinez, A. (2002) L-phenylalanine binding and
domain organization in human phenylalanine hydroxylase: a differential
scanning calorimetry study. Biochemistry (Mosc.), 41, 7573–7585.
30. Maier, E.M., Gersting, S.W., Kemter, K.F., Jank, J.M., Reindl, M.,
Messing, D.D., Truger, M.S., Sommerhoff, C.P. and Muntau, A.C. (2009)
Protein misfolding is the molecular mechanism underlying MCADD
identified in newborn screening. Hum. Mol. Genet., 18, 1612–1623.
31. Fontana, A., de Laureto, P.P., Spolaore, B., Frare, E., Picotti, P. and
Zambonin, M. (2004) Probing protein structure by limited proteolysis.
Acta Biochim. Pol., 51, 299–321.
32. Mitnaul, L.J. and Shiman, R. (1995) Coordinate regulation of
tetrahydrobiopterin turnover and phenylalanine hydroxylase activity in rat
liver cells. Proc. Natl Acad. Sci. USA, 92, 885–889.
33. Xia, T., Gray, D.W. and Shiman, R. (1994) Regulation of rat liver
phenylalanine hydroxylase. III. Control of catalysis by
(6R)-tetrahydrobiopterin and phenylalanine. J. Biol. Chem., 269, 24657–
24665.
34. Shiman, R. and Gray, D.W. (1980) Substrate activation of phenylalanine
hydroxylase. A kinetic characterization. J. Biol. Chem., 255, 4793–4800.
35. Stokka, A.J., Carvalho, R.N., Barroso, J.F. and Flatmark, T. (2004)
Probing the role of crystallographically defined/predicted hinge-bending
regions in the substrate-induced global conformational transition and
catalytic activation of human phenylalanine hydroxylase by single-site
mutagenesis. J. Biol. Chem., 279, 26571–26580.
36. Stokka, A.J. and Flatmark, T. (2003) Substrate-induced conformational
transition in human phenylalanine hydroxylase as studied by surface
plasmon resonance analyses: the effect of terminal deletions, substrate
analogues and phosphorylation. Biochem. J., 369, 509–518.
37. Andersen, O.A., Flatmark, T. and Hough, E. (2001) High resolution
crystal structures of the catalytic domain of human phenylalanine
hydroxylase in its catalytically active Fe(II) form and binary complex with
tetrahydrobiopterin. J. Mol. Biol., 314, 279–291.
38. Teigen, K. and Martinez, A. (2003) Probing cofactor specificity in
phenylalanine hydroxylase by molecular dynamics simulations. J. Biomol.
Struct. Dyn., 20, 733–740.
39. Kaufman, S. (1993) The phenylalanine hydroxylating system. Adv.
Enzymol. Relat. Areas Mol. Biol., 67, 77–264.
40. Pey, A.L., Ying, M., Cremades, N., Velazquez-Campoy, A., Scherer, T.,
Tho¨ny, B., Sancho, J. and Martinez, A. (2008) Identification of
pharmacological chaperones as potential therapeutic agents to treat
phenylketonuria. J. Clin. Invest., 118, 2858–2867.
41. Miranda, F.F., Teigen, K., Thorolfsson, M., Svebak, R.M., Knappskog,
P.M., Flatmark, T. and Martinez, A. (2002) Phosphorylation and
mutations of Ser(16) in human phenylalanine hydroxylase. Kinetic and
structural effects. J. Biol. Chem., 277, 40937–40943.
Human Molecular Genetics, 2010, Vol. 19, No. 10 2049
